
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): November 5, 2007

InfuSystem Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction of
incorporation)

0-51902
(Commission File Number)

20-3341405
(I.R.S. Employer Identification No.)

350 Madison Avenue
New York, New York 10017
(Address of Principal Executive Offices)(Zip Code)

(212) 418-5070
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 5, 2007, the Board of Directors of InfuSystem Holdings, Inc. (the “Company”) appointed Sean Whelan, 37, to serve as the Company’s Chief Financial Officer effective November 12, 2007. Prior to joining the Company, Mr. Whelan held senior finance positions with Ford Motor Company since 1996. Mr. Whelan has a Bachelor of Business Administration degree and a Master of Accounting degree, both from the University of Michigan Ross School of Business. Mr. Whelan received his Certified Public Accountant certificate in 1995 and his Certified Internal Auditor certificate in 1996.

Item 7.01 Regulation FD Disclosure

On November 5, 2007, the Company issued a press release announcing Sean Whelan’s appointment as Chief Financial Officer of the Company. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Released issued by InfuSystem Holdings, Inc. on November 5, 2007

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAPC, INC.

By: /s/ Steven Watkins

Name: Steven Watkins

Title: Chief Executive Officer

Dated: November 9, 2007

EXHIBIT LIST

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by InfuSystem Holdings, Inc. on November 5, 2007

**For Immediate Release****Investors:**

David K. Waldman/Klea K. Theoharis
Crescendo Communications, LLC
Tel: (212) 671-1020

**INFUSYSTEM HOLDINGS APPOINTS SEAN M. WHELAN, CPA
AS CHIEF FINANCIAL OFFICER**

New York, November 5, 2007 — **InfuSystem Holdings, Inc. (OTCBB: HAPN, HAPNW, HAPNU)**, the leading provider of ambulatory infusion pump services for administering chemotherapy, today announced the appointment of Sean M. Whelan, CPA, to the position of chief financial officer. Mr. Whelan replaces Erin Enright who held the position through the successful completion of the InfuSystem acquisition.

Prior to joining InfuSystem, Mr. Whelan held senior finance positions with Ford Motor Company since 1996. Most recently, he served as accounting director for Automotive Components Holdings, LLC, a subsidiary of Ford Motor Company, where he had direct oversight, financial and divestiture responsibility for the \$5.0 billion entity. During 2005, he led the due diligence effort and overall acquisition accounting pertaining to Ford's acquisition of Visteon's 24 North American facilities. Mr. Whelan also held senior treasury roles at Ford Motor Company, where he was responsible for managing the interest rate risk and funding strategy for Ford Credit, with over \$150 billion in assets. Prior to joining Ford Motor Company, Mr. Whelan was employed as a senior auditor for Deloitte & Touche, LLP from 1992 to 1995. Mr. Whelan has a Bachelor of Business Administration degree and a Master of Accounting degree, both from the University of Michigan Ross School of Business. Mr. Whelan received his CPA certificate in 1995, his Certified Internal Auditor certificate in 1996 and has been 6-Sigma Black Belt certified since 2000.

Sean McDevitt, chairman of InfuSystem Holdings, stated, "Sean's exposure to all aspects of corporate finance, his leadership skills and hands-on approach make him a terrific fit for InfuSystem. Sean has a proven track record at improving operational efficiencies, as well as evaluating and integrating acquisitions. We are honored to welcome Sean aboard at such an exciting time and look forward to his valuable contributions to the company."

Mr. Whelan commented, "I welcome the opportunity to serve as chief financial officer of InfuSystem Holdings and look forward to contributing to the team effort as we promote the benefits of ambulatory infusion pump services. I believe the company has a solid business plan in place to increase market penetration and expand its industry leading services into additional cancer markets and I am pleased to be a part of this important mission."

About InfuSystem Holdings, Inc.

InfuSystem provides external ambulatory infusion pump services to doctors and their patients allowing for the gradual delivery of a drug over a period of days in the privacy of one's home, rather than higher dose treatments, as is the case of chemotherapy administered in a hospital setting or doctor's office.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.

#